A study from the Keck School of Medicine of USC finds that a peptide only found in Old World monkeys has the potential to stop rheumatoid arthritis progression better than established treatments
In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa. It was a particular peptide only found in Old World monkeys, called ?-defensin 1 (RTD-1), that the researchers believed had the potential to stop — or even reverse — the progression of rheumatoid arthritis, an autoimmune disease that affects about 1.5 million people in the United States. The promising results of their study were published today in PLOS ONE.
“RTD-1 is the prototype of a family of small cyclic peptides (?-defensins), the only circular proteins in the animal kingdom,” says study author Michael Selsted, MD, PhD, chair and professor of pathology at the Keck School. “Previous studies have shown that RTD-1 modulates lethal inflammation in animal models of infection, and we predicted that RTD-1’s protective mechanism in those models would translate to rheumatoid arthritis, a disease in which chronic inflammation produces irreversible joint damage.”
To test their hypothesis, the researchers administered RTD-1 to rats with arthritis for 11 days and observed whether the treatment had any anti-arthritic effects. Within 24 hours of the first administered dose, RTD-1 had significantly reduced arthritis progression. At the end of the treatment, rats that received RTD-1 also had markedly lower arthritis severity scores as compared with rats that had not received RTD-1.
Next, RTD-1 was tested in rats with severe arthritis. The research team found that RTD-1 produced a rapid reduction in arthritis severity within 48 hours of treatment, with complete resolution of clinical disease in all treated rats by day 15.
RTD-1 was then compared to two gold standard treatments for rheumatoid arthritis — methotrexate and etanercept — in rats with severe arthritis. The team found that RTD-1 treatment resulted in greater disease resolution than methotrexate or etanercept. RTD-1 also achieved the highest rate of complete disease resolution of the three treatments.
“Since most available rheumatoid arthritis therapies achieve mild to moderate improvements, and disease remission is rare, there’s a continuing search for new therapeutics,” Selsted says. “Our findings strongly suggest that RTD-1 has potential as a completely new agent for treating rheumatoid arthritis. RTD-1-like molecules may also be effective in the treatment of other inflammatory diseases and cancer.”
The Latest on: RTD-1
- Johnnie St. Vrain: The ABD's of Longmont sales taxes on December 20, 2017 at 7:58 am
In Longmont, shoppers pay a combined sales tax rate of 8.26 percent. Here that is, broken down: city, 3.275 percent; state, 2.9 percent; RTD, 1 percent; county, 0.985 percent; SCFD (cultural district) ... […]
- 1/8 DIN Temperature Meters offer read rate of 60 conversions per second. on May 23, 2017 at 5:00 pm
SHIMPO INSTRUMENTS, A Division of NIDEC-SHIMPO AMERICA CORP., has released its new PM-THC & PM-RTD 1/8 DIN Temperature Meters with Jumper-Selectable Thermocouple or RTD Input. The PM Series is a versa... […]
- A Cyclic Antimicrobial Peptide Produced in Primate Leukocytes by the Ligation of Two Truncated α-Defensins on June 26, 2016 at 2:32 pm
The peptide, termed rhesus theta defensin-1 (RTD-1), is microbicidal for bacteria and fungi at low micromolar concentrations. Antibacterial activity of the cyclic peptide was threefold greater than th... […]
- JST to fund three coordinated EU-Japan research projects on August 29, 2013 at 5:00 pm
On the 30th August 2013, Japan Science and Technology Agency (JST) and the European Commission Directorate-General for Research and Innovation (EC DG RTD) *1 announced that they would commence support ... […]
via Google News and Bing News